News
Form 8.3 - The Vanguard Group, Inc.: Hibernian REIT plc
Form 8.3 - The Vanguard Group, Inc.: Workspace Group plc
Form 8.3 - The Vanguard Group, Inc.: Vivo Energy plc
Form 8.3 - The Vanguard Group, Inc.: Ultra Electronics Holdings plc
Philip Morris International Inc. (PMI) Reports 2022 First-Quarter Results
Regulatory News:
Philip Morris International Inc. (NYSE: PM) today announces its 2022 first-quarter results. Growth rates presented in this press release on an organic basis reflect
US Foods Reports Preliminary First Quarter Fiscal Year 2022 Earnings
US Foods Holding Corp. (NYSE: USFD), one of the largest foodservice distributors in the United States, today announced preliminary first quarter fiscal year 2022 results1. The Company will announce
Form 8.3 - The Vanguard Group, Inc.: Stagecoach Group plc
Form 8.3 - The Vanguard Group, Inc.: Sanne Group plc
Form 8.3 - The Vanguard Group, Inc.: Playtech plc
DGAP-Adhoc: ROY Asset Holding SE: Successful conclusion of a social plan and reconciliation of interests at Dekoramik Klingenberg GmbH
Form 8.3 - The Vanguard Group, Inc.: National Express Group plc
Form 8.3 - The Vanguard Group, Inc.: Meggitt plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
Form 8.3 - The Vanguard Group, Inc.: GXO Logistics, Inc.
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
Form 8.3 - The Vanguard Group, Inc.: Avast plc
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
DGAP-News: 2G Energy AG lifts Q1 new order intake to EUR 53.6 million (previous year: EUR 46.4 million)
DGAP-Adhoc: 2G Energy AG plans share split following a capital increase from company funds
PAO Severstal: Information regarding GDR program
DGAP-News: US-based energy company chooses USU to optimize software licenses
DGAP-Adhoc: InTiCa Systems AG: InTiCa Systems AG plans conversion into a European Company ('SE')
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the publication of a peer-reviewed article